Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, – Pipeline Review, H2 2016’, provides in depth analysis on Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, targeted pipeline therapeutics.

The report provides comprehensive information on the Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review,, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review,

The report reviews Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, targeted therapeutics and enlists all their major and minor projects

The report assesses Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review,

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Pipeline Review, development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Actelion Ltd

Arena Pharmaceuticals, Inc.

AstraZeneca Plc

Bristol-Myers Squibb Company

Celgene Corporation

GlaxoSmithKline Plc

Novartis AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) Overview 8

Therapeutics Development 9

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Products under Development by Stage of Development 9

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Products under Development by Therapy Area 10

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Products under Development by Indication 11

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Products under Development by Companies 15

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development 24

Actelion Ltd 24

Arena Pharmaceuticals, Inc. 25

AstraZeneca Plc 26

Bristol-Myers Squibb Company 27

Celgene Corporation 28

GlaxoSmithKline Plc 29

Novartis AG 30

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles 31

AKP-11 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

BMS-986104 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CBP-307 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Cenerimod - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CP-9531 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

etrasimod arginine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

NIBR-0213 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ozanimod hydrochloride - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ponesimod - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

siponimod - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecule to Agonize S1PR1 for Multiple Sclerosis - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Projects 57

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products 59

Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Featured News & Press Releases 60

Sep 29, 2016: Actelion To Investigate All-Oral Combination Therapy For Patients With Relapsing Multiple Sclerosis 60

Sep 17, 2016: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients 62

Sep 16, 2016: Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS 63

Aug 25, 2016: Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS 64

Jun 13, 2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 65

May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis 65

Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial 66

Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS 68

Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases 69

Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis 69

Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases 70

Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week 70

Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session 71

Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod 73

Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Actelion Ltd, H2 2016 24

Pipeline by Arena Pharmaceuticals, Inc., H2 2016 25

Pipeline by AstraZeneca Plc, H2 2016 26

Pipeline by Bristol-Myers Squibb Company, H2 2016 27

Pipeline by Celgene Corporation, H2 2016 28

Pipeline by GlaxoSmithKline Plc, H2 2016 29

Pipeline by Novartis AG, H2 2016 30

Dormant Projects, H2 2016 57

Dormant Projects (Contd..1), H2 2016 58

Discontinued Products, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared